Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
Stevens
Richard G
RG
Pretlow
Theresa P
TP
Hurlstone
D Paul
DP
Giardina
Charles
C
Rosenberg
Daniel W
DW
D000236:Adenoma / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D000068579:Celecoxib; D018890:Chemoprevention / Q000379:methods; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control*; D032921:Consensus; D055088:Early Detection of Cancer; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology*; D011230:Precancerous Conditions / Q000175:diagnosis* / Q000473:pathology; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D015415:Biomarkers; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib